Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Hepatitis C virus non-structural protein 3 (NS3) is a 70 kDa multifunctional enzyme produced by cleavage of the HCV polyprotein. It has two main functional domains: an N-terminal serine protease (involved in processing the viral polyprotein into mature non-structural proteins) and a C-terminal helicase/nucleoside triphosphatase (critical for viral RNA replication). The protease domain requires a cofactor, NS4A, for full activity. NS3 is an essential component of the HCV replication complex and a validated target for several clinically used direct-acting antiviral drugs. Its proper function is necessary for the life cycle of the hepatitis C virus, making it a central therapeutic target in HCV infection management.
Inhibition of NS3 serine protease activity, which disrupts viral polyprotein processing and prevents formation of the HCV replication complex
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Hepatitis C virus non-structural protein 3 (NS3).